Literature DB >> 12881583

Focal hepatic lesions: detection and characterization with combination gadolinium- and superparamagnetic iron oxide-enhanced MR imaging.

Myeong-Jin Kim1, Joo Hee Kim, Jae-Joon Chung, Mi Suk Park, Joon Seok Lim, Young Taik Oh.   

Abstract

PURPOSE: To compare gadolinium- and superparamagnetic iron oxide (SPIO)-enhanced magnetic resonance (MR) imaging for detection and characterization of focal hepatic lesions when different contrast agent administration sequences are used.
MATERIALS AND METHODS: Unenhanced, dynamic gadolinium-enhanced, and SPIO-enhanced hepatic MR images were obtained in 134 patients. SPIO-enhanced MR imaging was performed immediately after gadolinium-enhanced dynamic MR imaging in 50 patients, 1 day after gadolinium-enhanced dynamic MR imaging in 40 patients, and before gadolinium-enhanced dynamic MR imaging in 44 patients. Two radiologists independently reviewed the gadolinium image set (unenhanced and gadolinium-enhanced dynamic MR images) and the SPIO image set (unenhanced and SPIO-enhanced MR images) in random order. Lesion detection sensitivity and lesion characterization accuracy were compared by analyzing the area under the receiver operating characteristic curve (Az).
RESULTS: Overall lesion detection accuracy for pooled data was significantly higher with the SPIO set (Az = 0.903) than with the gadolinium set (Az = 0.857) (P <.05). When hypovascular lesions were excluded, the detection rate was similar with the two sets. When hepatocellular carcinomas were excluded, the detection rate was significantly higher with the SPIO set (P <.01). Readers were more accurate in differentiating benign from malignant lesions with the gadolinium set (Az = 0.915) than with the SPIO set (Az = 0.847) (P <.01). Detection accuracy tended to be better with the images obtained after the second contrast agent was used.
CONCLUSION: Hypovascular lesion detection was better with SPIO-enhanced MR images than with gadolinium-enhanced MR images. Detection and characterization of hypervascular lesions were improved with gadolinium-enhanced MR images.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12881583     DOI: 10.1148/radiol.2283020735

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  15 in total

Review 1.  [Current status of MRI diagnostics with liver-specific contrast agents. Gd-EOB-DTPA and Gd-BOPTA].

Authors:  C Stroszczynski; G Gaffke; M Gnauck; F Streitparth; G Wieners; E Lopez-Häninnen
Journal:  Radiologe       Date:  2004-12       Impact factor: 0.635

2.  Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist(®))-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre.

Authors:  V O Chan; J P Das; J F Gerstenmaier; J Geoghegan; R G Gibney; C D Collins; S J Skehan; D E Malone
Journal:  Ir J Med Sci       Date:  2012-03-17       Impact factor: 1.568

3.  Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine.

Authors:  G Park; Y K Kim; C S Kim; H C Yu; S B Hwang
Journal:  Br J Radiol       Date:  2010-08-03       Impact factor: 3.039

Review 4.  Imaging diagnosis of colorectal liver metastases.

Authors:  Ling-Hui Xu; San-Jun Cai; Guo-Xiang Cai; Wei-Jun Peng
Journal:  World J Gastroenterol       Date:  2011-11-14       Impact factor: 5.742

Review 5.  Liver metastases: Contrast-enhanced ultrasound compared with computed tomography and magnetic resonance.

Authors:  Vito Cantisani; Hektor Grazhdani; Cristina Fioravanti; Maria Rosignuolo; Fabrizio Calliada; Daniela Messineo; Maria Giulia Bernieri; Adriano Redler; Carlo Catalano; Ferdinando D'Ambrosio
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

6.  Treatment response classification of liver metastatic disease evaluated on imaging. Are RECIST unidimensional measurements accurate?

Authors:  Michael Mantatzis; Stylianos Kakolyris; Kyriakos Amarantidis; Anastasios Karayiannakis; Panos Prassopoulos
Journal:  Eur Radiol       Date:  2009-02-24       Impact factor: 5.315

Review 7.  Imaging of liver cancer.

Authors:  Ben Ariff; Claire R Lloyd; Sameer Khan; Mohamed Shariff; Andrew V Thillainayagam; Devinder S Bansi; Shahid A Khan; Simon D Taylor-Robinson; Adrian K P Lim
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

8.  MR characterisation of dysplastic nodules and hepatocarcinoma in the cirrhotic liver with hepatospecific superparamagnetic contrast agents: pathological correlation in explanted livers.

Authors:  L Macarini; P Milillo; A Cascavilla; G Scalzo; L Stoppino; R Vinci; G Moretti; G Ettorre
Journal:  Radiol Med       Date:  2009-11-09       Impact factor: 3.469

9.  Small (<or=3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT.

Authors:  R Golfieri; E Marini; A Bazzocchi; F Fusco; F Trevisani; C Sama; G Mazzella; S Cavuto; F Piscaglia; L Bolondi
Journal:  Radiol Med       Date:  2009-08-20       Impact factor: 3.469

10.  Diagnostic accuracy of MR imaging to identify and characterize focal liver lesions: comparison between gadolinium and superparamagnetic iron oxide contrast media.

Authors:  Simone Maurea; Pier Paolo Mainenti; Annamaria Tambasco; Massimo Imbriaco; Carmine Mollica; Ettore Laccetti; Luigi Camera; Raffaele Liuzzi; Marco Salvatore
Journal:  Quant Imaging Med Surg       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.